Trastuzumab deruxtecan

About

Therapy type: Targeted therapy

Therapy strategy: HER2 inhibition

Mappings

NCI Thesaurus: Trastuzumab Deruxtecan (coding:ncit:C128799)

RxNorm: trastuzumab deruxtecan (coding:rxcui:2267582, coding:omop:37498192)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) FDA (2) HER2-positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) FDA (2) HER2-low Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) FDA (2) ERBB2 activating variants Non-Small Cell Lung Cancer Trastuzumab deruxtecan
EMA (1) FDA (2) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan
EMA (1) FDA (2) HER2-positive Any solid tumor Trastuzumab deruxtecan
EMA (1) ERBB2 amplification Non-Small Cell Lung Cancer Trastuzumab deruxtecan
EMA (1) ERBB2 amplification Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan
EMA (1) ER positive, HER2-low Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-low, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-ultralow Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
EMA (1) ER positive, HER2-ultralow, PR positive Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (2) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab deruxtecan